Advancing Aseptic Manufacturing: GRAM’s Vision for the Future of Sterile Drug Production
GRAM is expanding capacity with a new 150,000 sq. ft. syringe and cartridge filling center, expected to be operational by 2026.
The company is investing in advanced automation, robotics, and isolator technology to enhance sterility assurance and operational efficiency.
GRAM is focusing on flexible manufacturing solutions to accommodate smaller batch sizes and complex biologics.
Strategic partnerships, like GRAM's collaboration with LTS on the Sorrel device, are enabling innovations in drug delivery systems.
The company is adapting to evolving regulatory standards, including Annex 1 revisions for aseptic processing.
GRAM is emphasizing patient-centric drug delivery solutions, including pre-filled syringes and auto-injectors for at-home administration.
The company has grown to over 450,000 sq. ft. of production space across five manufacturing facilities in Grand Rapids, Michigan.
GRAM is positioning itself to meet increasing demand for high-quality aseptic manufacturing of complex biologics and biosimilars.